An actinic ray-sensitive or radiation-sensitive resin composition contains a compound represented by General Formula (I). In General Formula (I), R.sub.a and R.sub.b each independently represent a hydrogen atom or a substituent, provided that R.sub.a and R.sub.b satisfy the following requirement (1) or (2): (1) at least one of R.sub.a or R.sub.b represents a secondary alkyl group, a tertiary alkyl group, a cycloalkyl group, or a perfluoroalkyl group, and R.sub.a and R.sub.b may be bonded to each other to form a ring, and (2) R.sub.a and R.sub.b are bonded to each other to form a ring, R.sub.c represents a substituent, L.sub.0 represents a single bond or a divalent linking group, L.sub.1 represents a single bond or a divalent linking group, L.sub.2 represents a single bond or a divalent linking group, nM.sup.+ represents an organic cationic moiety, and n represents an integer of 1 or more.

The invention concerns a method for treatment of a stream of mixed compounds (4a) obtained from a process (3) comprising decomposition and/or conversion of a wood or pulp material, the method comprising: feeding the stream (4a-4e) through a processing arrangement (2) comprising one or more treatment units (10, 20, 30, 40, 50) arranged to separate at least a first compound from other compounds in the stream and form a first product flow (4f) containing the first compound, wherein the one or more treatment units comprises at least a first primary separation unit (20) arranged to separate one or more compounds other than the first compound from the stream; and feeding the compounds separated from the first compound in the first primary separation unit (20) to a first auxiliary separation unit (21) so as to separate a second compound from at least one of the other compounds separated from the first compound in the first primary separation unit (20) and thereby increase the purity of said second compound and form a second product flow (22, 23) in the form of a purified second compound and/or a purified derivative of the second compound, wherein the second compound is dimethyl sulfide (DMS, CH3—S—CH3), methyl mercaptan (CH3—S—H) or acetone (CH3—CO—CH3).

The invention concerns a method for treatment of a stream of mixed compounds (4a) obtained from a process (3) comprising decomposition and/or conversion of a wood or pulp material, the method comprising: feeding the stream (4a-4e) through a processing arrangement (2) comprising one or more treatment units (10, 20, 30, 40, 50) arranged to separate at least a first compound from other compounds in the stream and form a first product flow (4f) containing the first compound, wherein the one or more treatment units comprises at least a first primary separation unit (20) arranged to separate one or more compounds other than the first compound from the stream; and feeding the compounds separated from the first compound in the first primary separation unit (20) to a first auxiliary separation unit (21) so as to separate a second compound from at least one of the other compounds separated from the first compound in the first primary separation unit (20) and thereby increase the purity of said second compound and form a second product flow (22, 23) in the form of a purified second compound and/or a purified derivative of the second compound, wherein the second compound is dimethyl sulfide (DMS, CH3—S—CH3), methyl mercaptan (CH3—S—H) or acetone (CH3—CO—CH3).

The present inventors found cyclic peptide compounds that interact with Ras, and non-natural amino acids useful for the production of the cyclic peptide compounds. The inventors also found that the cyclic peptide compounds inhibit the binding between Ras and SOS. In addition, the inventors found specific non-natural amino acids contained in the cyclic peptide compounds and methods for production thereof.

The present inventors found cyclic peptide compounds that interact with Ras, and non-natural amino acids useful for the production of the cyclic peptide compounds. The inventors also found that the cyclic peptide compounds inhibit the binding between Ras and SOS. In addition, the inventors found specific non-natural amino acids contained in the cyclic peptide compounds and methods for production thereof.

The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.

The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.

Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are tocopherol quinone derivatives. Further disclosed are compounds, compositions, and methods for treatment of, or prophylaxis against, radiation exposure.

Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are tocopherol quinone derivatives. Further disclosed are compounds, compositions, and methods for treatment of, or prophylaxis against, radiation exposure.

A cannabinoid formulation and method for ocular or nasal delivery. The method of administration includes providing eye drops that comprise an aqueous solution of at least one water soluble cannabinoid, saline, and a vasodilator; and administering the eye drops topically to an eye of the subject. In an alternate method the cannabinoid formulation is a nasal spray delivered through the nose of a subject. Preferably, the vasodilator is 0.9% methylsulfonylmethane (MSM) in a MSM solution so that the MSM solution has a concentration of 5-15% in the overall formulation. Additionally, the at least one water soluble cannabinoid is encapsulated with a phospholipid liposome.